English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Sihuan Pharma Approved for China Trials of Innovative Cancer Drug

Oct. 10, 2013

Sihuan announced on October 10, 2013 that Pirotinib, a Category 1.1 innovative drug which is developed by its innovative drug R&D team, was cleared for clinical trials by the CFDA. Pirotinib is a second generation pan-Her inhibitor for the indications of lung and breast cancer. Sihuan’s pre-clinical studies demonstrated that Pirotinib has superior profiles in pharmacology, pharmacokinetics and toxicology with a developable property.